|
Forecast
Period
|
2025-2029
|
|
Market
Size (2023)
|
USD
571.03 billion
|
|
CAGR
(2023-2028)
|
7.36%
|
|
Fastest
Growing Segment
|
Consumables
|
|
Largest
Market
|
North
India
|
Market Overview
India Cancer Diagnostics Market has valued at USD 571.03
billion in 2022 and is anticipated to project robust growth in the forecast
period with a CAGR of 7.36% through 2029. Cancer Diagnostics are designed to
enhance the regular diet by providing individuals with the necessary daily
nutritional value. Vitamins play crucial roles in the development and proper
functioning of the body, acting as hormones, coenzymes, and antioxidants.
Various factors such as shifting dietary preferences, busy lifestyles, rising
employment rates, and increased awareness of the health benefits associated
with Cancer Diagnostics are expected to positively influence the India market
growth.
Due to hectic schedules, many individuals struggle
to maintain a balanced diet, resulting in nutrient deficiencies. Consequently,
there has been a significant rise in the consumption of Cancer Diagnostics to
fulfill daily nutrient and vitamin requirements, promoting overall health and
vitality. Furthermore, the increasing healthcare expenditure worldwide is
anticipated to drive the demand for Cancer Diagnostics. Additionally, the
growing elderly population in both developed and developing economies presents
lucrative opportunities for market players in the forecast period. The senior
population, in particular, relies on Cancer Diagnostics to meet their dietary
needs, promote bone health, and support overall well-being.
Key Market Drivers
Increasing Cancer Incidence
India has witnessed a rising incidence of cancer,
partly due to lifestyle factors, environmental pollution, and an aging
population. India's population has been steadily growing, and with it, the
proportion of elderly individuals. Aging is a well-known risk factor for
cancer, as cellular changes over time can increase the likelihood of
malignancies. This demographic shift has contributed to the increased cancer
burden in the country.
Urbanization and the adoption of Western lifestyles
have brought about significant changes in dietary habits and physical activity
levels among Indians. Diets high in processed foods, low in fruits and
vegetables, and sedentary lifestyles are associated with higher cancer risk.
The prevalence of these factors has contributed to the rising cancer incidence.
Environmental pollution, exposure to carcinogens, and industrialization have
led to increased cancer risk. Pollutants such as air pollutants, pesticides,
and chemicals in groundwater can contribute to the development of cancer. As
industrialization continues, these environmental factors become more
pronounced. A lack of awareness about cancer symptoms and the importance of
regular screenings has delayed diagnoses in many cases. Late-stage cancer
diagnoses often result in more aggressive treatment and poorer outcomes. As
awareness campaigns increase, more individuals are seeking early detection,
which is a positive step toward mitigating the impact of cancer.
The escalating cancer incidence in India has
profound implications for the cancer diagnostics market in the country. With
more individuals at risk of cancer, there is a growing demand for diagnostic services.
This includes screening tests, imaging studies, and laboratory diagnostics.
Healthcare providers are investing in advanced diagnostic technologies to meet
this demand. To keep pace with the rising cancer burden, there have been
significant advancements in diagnostic technologies. From state-of-the-art
imaging modalities to molecular diagnostics, these innovations aid in early
detection and precise diagnosis, improving patient outcomes. The surge in
cancer incidence has prompted increased investments in cancer research and
development in India. This includes the development of new diagnostic tests,
therapies, and treatment modalities. As a result, the cancer diagnostics market
is becoming more robust and competitive. The increasing cancer incidence in
India presents substantial growth opportunities for companies operating in the
cancer diagnostics sector. Market players are expanding their portfolios,
collaborating with research institutions, and enhancing their presence to cater
to the growing demand for diagnostic solutions.
Awareness and Early Detection
Growing awareness about cancer and the importance
of early detection has led to more people seeking diagnostic services. Awareness
campaigns and initiatives have played a pivotal role in educating the Indian
population about cancer and the importance of early detection. Various
non-governmental organizations (NGOs), healthcare institutions, and government
bodies have been actively involved in raising awareness about cancer risk
factors, symptoms, and available screening methods. These efforts have led to a
noticeable shift in public perception and behavior.
One of the significant challenges in India's battle
against cancer has been the prevailing cultural and social stigmas associated
with the disease. Historically, cancer was often considered a taboo topic,
leading to delayed healthcare seeking behavior. However, increased awareness
campaigns have helped change societal mindsets. People are now more open to
discussing cancer, which has led to earlier diagnosis and treatment. In
response to the rising cancer incidence, India has seen the implementation of
various early detection programs. These programs target specific types of
cancer that are prevalent in certain regions or among particular demographics.
Examples include breast cancer screening camps for women and tobacco cessation
programs for high-risk populations. These initiatives aim to catch cancer at
its earliest, most treatable stages.
Awareness campaigns have not only educated the
public but have also paved the way for improved access to cancer screening
services. Mobile cancer screening units, diagnostic clinics, and specialized
cancer centers have become more prevalent. This increased accessibility ensures
that individuals can undergo necessary screenings conveniently and affordably. Early
detection is often synonymous with improved patient outcomes in cancer cases.
When cancer is identified in its early stages, it is typically more treatable,
and the chances of complete remission are significantly higher. This positive
correlation between early detection and better survival rates has motivated
individuals to seek screenings and healthcare providers to invest in advanced
diagnostic technologies.
The heightened awareness about cancer and the
importance of early detection has led to a surge in demand for cancer screening
services. This includes screenings for breast cancer, cervical cancer,
colorectal cancer, and other prevalent types. As more individuals recognize the
value of early diagnosis, the market for cancer diagnostic tests and procedures
continues to expand. To cater to the growing demand for early cancer detection,
the market has witnessed the development of specialized diagnostic tests. These
tests are designed for early-stage cancer detection and offer higher
sensitivity and specificity. Examples include liquid biopsy tests for detecting
circulating tumor DNA, which can identify cancer at its earliest stages. Healthcare
institutions and diagnostic service providers have recognized the need to
invest in screening infrastructure. This includes acquiring state-of-the-art
imaging equipment, laboratory facilities, and skilled personnel to meet the
rising demand for cancer screenings. Such investments not only improve
diagnostic accuracy but also contribute to market growth. Companies operating
in the cancer diagnostics sector have increasingly collaborated with healthcare
organizations and NGOs to support awareness campaigns. These partnerships
amplify the reach of awareness initiatives and drive more individuals to seek
early detection services, further fueling market growth.
Advancements in Technology
The availability of advanced diagnostic
technologies and tools has improved the accuracy and precision of cancer
diagnostics. the key areas where technological advancements have made a
significant impact in cancer diagnostics is medical imaging. High-resolution
imaging techniques such as Magnetic Resonance Imaging (MRI), Computed
Tomography (CT) scans, and Positron Emission Tomography (PET) scans have
undergone substantial improvements. These innovations provide detailed insights
into the structure and function of tissues, aiding in early cancer detection
and precise diagnosis. Advances in molecular diagnostics have revolutionized
cancer detection and treatment. Techniques like Polymerase Chain Reaction (PCR)
and Next-Generation Sequencing (NGS) allow for the analysis of genetic and
molecular markers associated with cancer. This enables healthcare providers to
identify specific mutations and tailor treatments to individual patients,
leading to more effective therapies and better outcomes.
Liquid biopsies represent a groundbreaking
advancement in cancer diagnostics. These non-invasive tests analyze circulating
tumor DNA (ctDNA) or other biomarkers present in bodily fluids like blood.
Liquid biopsies offer a minimally invasive way to detect and monitor cancer,
making them particularly valuable for early diagnosis and tracking treatment
response. The integration of AI and machine learning algorithms into cancer
diagnostics has enhanced the accuracy and efficiency of data analysis. These
technologies can analyze vast amounts of medical data, identify patterns, and
assist radiologists and pathologists in interpreting imaging and pathology
reports. This not only reduces human error but also speeds up the diagnostic
process. The COVID-19 pandemic accelerated the adoption of telemedicine and
remote consultations in healthcare, including cancer diagnostics. Patients can
now connect with oncologists and specialists remotely, allowing for timely
consultations, follow-ups, and treatment planning. This technology-driven
approach has improved access to cancer care, especially in remote or
underserved areas. Advancements in point-of-care testing have enabled rapid and
accurate cancer diagnosis at the patient's bedside or in smaller healthcare
facilities. These portable devices can detect cancer biomarkers quickly,
reducing the time required for diagnosis and enabling immediate treatment
decisions.
The integration of advanced technologies in cancer
diagnostics has significantly improved diagnostic accuracy. This is crucial for
identifying cancer at its earliest, most treatable stages, and for guiding
personalized treatment strategies. Patients can benefit from more precise
diagnoses and tailored therapies, ultimately leading to better outcomes. Technological
advancements have led to faster turnaround times for diagnostic tests. Rapid
and efficient testing processes ensure that patients receive timely results,
enabling prompt initiation of treatment when necessary. This speed is
particularly critical in cancer diagnosis, where early intervention can be
lifesaving. The growing demand for technologically advanced cancer diagnostics
has spurred market expansion in India. Companies specializing in diagnostic
equipment, software, and services have witnessed increased demand for their
products. This has led to greater investments in research and development,
further driving innovation in the sector. Technological advancements have also
improved the accessibility of cancer diagnostics. Telemedicine and
point-of-care testing have made it easier for individuals in remote or
underserved areas to access quality diagnostic services. This broader outreach
helps in early detection and ensures that more patients receive appropriate
care. Indian healthcare institutions and diagnostic companies are increasingly
collaborating with global technology leaders to adopt and implement
cutting-edge diagnostic solutions. This collaboration not only enhances the
quality of cancer diagnostics but also fosters international partnerships that
benefit the Indian healthcare ecosystem.
Government Initiatives
Initiatives such as the National Cancer Control
Programme (NCCP) and Ayushman Bharat have increased access to cancer
diagnostics and treatment. The cornerstone of government efforts in India's
fight against cancer is the National Cancer Control Program (NCCP). This
comprehensive initiative aims to combat cancer through prevention, early
detection, treatment, and palliative care.
The government conducts extensive awareness
campaigns to educate the public about cancer risk factors, symptoms, and the
importance of early detection. These campaigns have been instrumental in
changing public attitudes and behaviors regarding cancer. NCCP supports the
implementation of cancer screening programs, such as breast cancer and cervical
cancer screenings for women. These initiatives aim to catch cancer at its early
stages when treatment is more effective. The government invests in building and
upgrading cancer treatment infrastructure, including cancer hospitals and
radiation therapy centers. This infrastructure expansion ensures that more
patients have access to quality cancer care. NCCP fosters research in cancer
prevention, diagnosis, and treatment. It also supports training programs for
healthcare professionals to enhance cancer management capabilities.
National Program for Prevention and Control of
Cancer, Diabetes, Cardiovascular Diseases, and Stroke (NPCDCS)
Under the NPCDCS, the government targets the
prevention and control of not only cancer but also other non-communicable
diseases. The program integrates cancer control efforts with the broader
context of non-communicable disease control. This ensures a holistic approach
to healthcare. The government invests in the training of healthcare workers,
equipping them with the knowledge and skills needed for cancer screening,
diagnosis, and treatment. NPCDCS provides financial support to states for
implementing cancer control activities, including screening and treatment
services.
Government initiatives, especially those related to
awareness and early detection, have led to a surge in demand for cancer
diagnostic services. As more individuals become aware of the importance of
screenings, the market for diagnostic tests and procedures has grown
significantly. Government investments in healthcare infrastructure have
expanded the availability of diagnostic facilities across the country. This
includes the establishment of cancer screening centers, diagnostic labs, and
radiology facilities. The improved infrastructure contributes to market growth.
Government programs often encourage collaboration between public and private
healthcare sectors. Diagnostic companies have opportunities to partner with
government agencies to provide testing services, equipment, and expertise. Such
collaborations can be mutually beneficial and drive market expansion. Government
support for cancer research not only advances our understanding of the disease
but also fuels innovation in cancer diagnostics. Research grants and incentives
encourage companies to develop cutting-edge diagnostic technologies, leading to
a more robust market. Government initiatives aim to make healthcare more
accessible to all segments of the population. This inclusivity ensures that
even underserved communities have access to cancer diagnostics, thereby
increasing market reach.
Download Free Sample Report
Key Market Challenges
Limited Healthcare Infrastructure
One of the primary challenges in the growth of the
India Cancer Diagnostics Market is the limited healthcare infrastructure,
especially in rural and underserved areas. While major cities have advanced
diagnostic facilities, a significant portion of the population in remote
regions lacks access to even basic healthcare services, including cancer
diagnostics.
The lack of infrastructure restricts the reach of
cancer diagnostic services. Patients in rural areas may face long travel
distances and high costs to access diagnostic centers in urban areas. This
hinders early detection and timely treatment, ultimately impacting market
growth. Government initiatives to expand healthcare infrastructure,
particularly in rural areas, can help mitigate this challenge. Investments in
building diagnostic centers, telemedicine services, and mobile clinics can
extend the reach of cancer diagnostics to underserved populations.
High Cost of Diagnostic Procedures
Cancer diagnostic procedures, especially advanced
imaging and molecular tests can be expensive. Many Indians, particularly those
from low-income backgrounds, may find the cost of these procedures prohibitive.
This cost barrier can deter individuals from seeking timely cancer screenings
and diagnostic tests.
The high cost of diagnostic procedures can result
in delayed diagnosis or the avoidance of screenings altogether. This, in turn,
may lead to cancer being detected at later, less treatable stages, impacting
patient outcomes and limiting market growth. To address this challenge,
healthcare providers and diagnostic companies can explore cost-effective
diagnostic solutions and offer subsidized or affordable screening programs.
Government subsidies and health insurance schemes can also help make cancer diagnostics
more accessible to a broader population.
Lack of Awareness and Stigma
Despite efforts to raise awareness, there is still
a significant lack of understanding and awareness about cancer in many parts of
India. Moreover, cultural and social stigmas associated with the disease
persist. This lack of awareness and stigma can discourage individuals from
seeking cancer diagnostic services, even when they experience symptoms.
A lack of awareness and stigma can lead to delayed
diagnoses and missed opportunities for early detection. Public education
campaigns and efforts to reduce stigma are essential for overcoming this
challenge and promoting early cancer screenings. Government and non-government
organizations can intensify their awareness campaigns, targeting both urban and
rural populations. These campaigns should emphasize the importance of early
detection and debunk myths surrounding cancer. Community outreach and education
programs can help reduce stigma and encourage individuals to seek cancer
diagnostics when needed.
Key Market Trends
Rise in Personalized Medicine and Targeted
Therapies
Personalized medicine and targeted therapies have
gained prominence in cancer diagnostics and treatment. Advancements in
molecular diagnostics and genomic profiling have allowed healthcare providers
to tailor cancer therapies to the specific genetic characteristics of a
patient's tumor. This trend is increasingly shaping the landscape of cancer
diagnostics in India.
The adoption of personalized medicine not only
improves treatment outcomes but also drives the demand for advanced diagnostic
tests that identify specific biomarkers and genetic mutations. Diagnostic
companies are developing tests that help oncologists select the most effective
treatments for individual patients, leading to increased market growth. Liquid
biopsies, which detect circulating tumor DNA, are gaining traction for
monitoring treatment response and identifying resistance mutations.
Additionally, companion diagnostics are becoming more common, guiding the use
of targeted therapies.
Telemedicine and Remote Consultations
The COVID-19 pandemic accelerated the adoption of
telemedicine and remote consultations in healthcare, including cancer
diagnostics. Telemedicine platforms and virtual consultations with oncologists
have become more accessible and accepted by patients, particularly those in
remote or underserved areas.
Telemedicine has expanded the reach of cancer
diagnostic services, allowing individuals to consult with specialists without
the need for long-distance travel. This trend enhances early detection by
ensuring that individuals from all geographical locations can access diagnostic
consultations and recommendations. Tele-oncology services provide expert
opinions and guidance for cancer diagnostics, treatment planning, and follow-up
care. Patients can undergo initial consultations and receive test results
remotely, improving the overall patient experience.
Artificial Intelligence (AI) and Machine Learning
Integration
The integration of artificial intelligence (AI) and
machine learning (ML) into cancer diagnostics is a growing trend in India.
These technologies analyze vast datasets, including medical images and
pathology reports, to assist radiologists and pathologists in diagnosing cancer
more accurately and efficiently.
AI and ML algorithms can detect subtle patterns and
anomalies in medical images, improving the accuracy of cancer diagnoses.
Additionally, they assist in risk prediction, early detection, and treatment
planning. The adoption of AI-driven diagnostic tools is enhancing the
capabilities of healthcare professionals and driving market growth. AI-powered
software can assist in mammography interpretations, lung nodule detection in CT
scans, and the analysis of histopathological slides. These tools expedite the
diagnostic process and reduce the risk of human error.
Segmental Insights
Product Insights
Based on the category of Product, the consumables
segment emerged as the dominant player in the India market for Cancer
Diagnostics in 2022. Cancer diagnostic reagents are
used in a variety of cancer diagnostic tests, such as immunohistochemistry, in
situ hybridization, and molecular diagnostics tests. The increasing prevalence
of cancer in India is driving the demand for cancer diagnostic reagents.
Growing
awareness of the importance of early diagnosis of cancer: Early diagnosis of
cancer is essential for improving patient outcomes. The growing awareness of
the importance of early diagnosis of cancer is driving the demand for cancer
diagnostic tests and reagents. The Indian government and private sector are
investing heavily in cancer diagnostics. This investment is leading to the
development of new cancer diagnostic tests and reagents and the expansion of
cancer diagnostic facilities. These factors are expected to drive the growth of
this segment.
Type Insight
Based on the category of Type, the IVD (in vitro
diagnostics) segment emerged as the dominant player in the India market for Cancer
Diagnostics in 2022. There is a wide range of IVD cancer diagnostic tests
available, including immunohistochemistry, in situ hybridization, and molecular
diagnostics tests. These tests are widely used in hospitals and clinics for the
diagnosis and monitoring of cancer. IVD cancer diagnostic tests are becoming
more widely available in India, due to the increasing investment in cancer
diagnostics by the Indian government and private sector. IVD cancer diagnostic
tests are generally more affordable than other types of cancer diagnostic
tests, such as LDTs and imaging tests. This makes them more accessible to
patients in India. These factors are expected to drive the growth of the
segment.
Application Insight
Based on the category of Application, the breast
cancer segment emerged as the dominant player in the India market for Cancer
Diagnostics in 2022. Breast cancer is the most common cancer among women in
India. According to the National Cancer Registry, breast cancer accounts for
approximately 29% of all cancers among women in India. Early diagnosis of
breast cancer is essential for improving patient outcomes. The growing
awareness of the importance of early diagnosis of breast cancer is driving the
demand for breast cancer diagnostic tests.
The Indian government and private sector are
investing heavily in breast cancer diagnostics. This investment is leading to
the development of new breast cancer diagnostic tests and the expansion of breast
cancer diagnostic facilities.
Test Type
Based on the category of Test Type, the Biopsy
segment emerged as the dominant player in the India market for Cancer
Diagnostics in 2022. A biopsy is a procedure in which a small sample of tissue
is removed from the body and examined under a microscope for cancer cells.
Biopsy is the most definitive way to diagnose cancer and is essential for
determining the type and stage of cancer. Increasing demand for biopsy tests:
The increasing prevalence of cancer in India is driving the demand for biopsy
tests. Growing awareness of the importance of early diagnosis of cancer: Early
diagnosis of cancer is essential for improving patient outcomes. The growing
awareness of the importance of early diagnosis of cancer is driving the demand
for biopsy tests.
End-User Insights
The hospital segment is projected to experience
rapid growth during the forecast period. Physicians, dieticians, and other
healthcare professionals are increasingly recommending Cancer Diagnostics to
their patients to enhance health and improve quality of life. Consequently,
prescription medicines are predominantly available in pharmacies, which is
expected to contribute to the growth of this segment. Moreover, the
hypermarkets/supermarkets segment is anticipated to present favorable growth
opportunities in the forecast period due to its wide acceptance among
end-users. Factors such as organized product display panels, consumers'
willingness to pay premium prices for specific products, and the strong
relationship between sales executives and buyers facilitate a better
understanding of consumer preferences for products and brands. These factors
collectively contribute to the growth of this segment.
Download Free Sample Report
Regional Insights
North India Segment emerged as the dominant player
in the India Cancer Diagnostics market in 2022, holding the largest market
share in terms of value. North India, particularly the
National Capital Region (NCR) and major cities like Delhi, has historically had
a more advanced healthcare infrastructure compared to other regions. The
presence of top-tier hospitals, cancer centers, and diagnostic laboratories in
these areas has contributed to the dominance of North India in the cancer
diagnostics market. Patients from neighbouring states often travel to North
India for specialized diagnostic services. North India hosts a significant
concentration of leading healthcare institutions, research centers, and medical
colleges. These institutions often serve as hubs for cancer diagnosis,
research, and treatment. Their expertise and state-of-the-art diagnostic
facilities attract patients from across the country. North India, including the
NCR, has a relatively higher population density compared to many other regions.
The larger population base translates to a higher number of potential patients
seeking cancer diagnostic services. This factor contributes to the dominance of
North India in terms of market size. North India, particularly urban areas,
has relatively higher awareness levels about cancer and the importance of early
detection. Additionally, the population in these areas often has better access
to healthcare insurance and financial resources, making them more likely to
afford advanced diagnostic tests. Leading medical institutions and research
centers in North India actively engage in cancer research and diagnostic
innovation. This environment fosters the development and adoption of
cutting-edge diagnostic technologies, further strengthening the region's
dominance in the market.
The South India segment is poised to be the
fastest-growing market, offering lucrative growth opportunities for Cancer
Diagnostics players during the forecast period. Factors such as South India,
particularly states like Karnataka, Tamil Nadu, and Kerala, has made
substantial investments in healthcare infrastructure. The region is home to
some of India's premier healthcare institutions, including hospitals, research
centers, and cancer treatment facilities. The presence of well-established
healthcare infrastructure is a significant driver of market growth. South India
boasts renowned medical colleges, universities, and research institutions.
These institutions actively engage in cancer research, diagnostic innovation,
and medical education. The research environment fosters the development and
adoption of cutting-edge diagnostic technologies. The literacy rate in South
India is generally higher than the national average. This region has a more
educated and health-conscious population, which translates to increased
awareness about cancer and the importance of early detection. Higher awareness
levels encourage individuals to seek cancer diagnostic services. Certain states
in South India have experienced economic prosperity, resulting in a population
with greater financial resources. The ability to afford advanced diagnostic
tests and treatments makes residents more likely to undergo screenings and
diagnostic procedures.
Recent Developments
- In August 2023: Bristol-Myers Squibb India
announced that it has received regulatory approval from the Drugs Controller
General of India (DCGI) for the launch of Zeposia® (ozanimod), a drug for the
treatment of relapsing-remitting multiple sclerosis (RRMS). Zeposia® is the
first oral, sphingosine 1-phosphate (S1P) receptor modulator to be approved in
India for the treatment of RRMS.
- In August 2023, 14.2. Bristol-Myers Squibb India Private Limited. is expanding its
manufacturing capacity in Ahmedabad, India. The expansion is expected to be
completed in 2024 and will double the company's production capacity for generic
injectables.
- In September 2023, Cipla has launched the generic
version of Evusheld (tixagevimab and cilgavimab), a monoclonal antibody
cocktail for the prevention of COVID-19. Evusheld is the first monoclonal
antibody cocktail to be launched in India for the prevention of COVID-19.
Key Market Players
- Baxter Pharmaceuticals India
Private Limited.
- Bristol-Myers
Squibb India Private Limited.
- Cipla
Ltd.
- Roche
Products (India) Private Limited.
- Glenmark
Pharmaceuticals Ltd.
- Lupin Ltd
- Abbott
India Laboratories
- BIO-RAD
LABORATORIES (INDIA) PRIVATE LIMITED.
- Siemens
Healthcare Private Limited.
- Thermo
Fisher Scientific India Private Limited.
|
By Product
|
By Type
|
By Application
|
By Test-Type
|
By End-User
|
By Region
|
- Instruments
- Consumables
- Services
|
|
- Breast Cancer
- Colorectal Cancer
- Cervical Cancer
- Lung Cancer
- Prostate Cancer
- Skin Cancer
- Blood Cancer
- Kidney Cancer
- Liver Cancer
- Pancreatic Cancer
- Ovarian Cancer
- Others
|
- Powder
- Tablets
- Capsules
- Soft gels
- Gummies
|
- Hospital Pharmacies
- Retail Pharmacies
- E-stores
- Hypermarkets/supermarkets
|
- North America
- Europe
- Asia Pacific
- South America
- Middle East & Africa
|
Report Scope:
In this report, the India Cancer Diagnostics Market
has been segmented into the following categories, in addition to the industry
trends which have also been detailed below:
- Cancer Diagnostics Market, By Product:
o Instruments
o Consumables
o Services
- Cancer Diagnostics Market, By Type:
o IVD
o LDT
o Imaging
- Cancer Diagnostics Market, By Application:
o Breast Cancer
o Colorectal Cancer
o Cervical Cancer
o Lung Cancer
o Prostate Cancer
o Skin Cancer
o Blood Cancer
o Kidney Cancer
o Liver Cancer
o Pancreatic Cancer
o Ovarian Cancer
o Others
- Cancer Diagnostics Market, By Test-Type:
o Biopsy
o Others
- Cancer Diagnostics Market, By End-User:
o Hospitals
o Laboratories
o Others
- Cancer Diagnostics Market, By Region:
o North India
o South India
o East India
o West India
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in the India Cancer
Diagnostics Market.
Available Customizations:
India Cancer Diagnostics market report with
the given market data, TechSci Research offers customizations according to a
company's specific needs. The following customization options are available for
the report:
Company Information
- Detailed analysis and profiling of additional
market players (up to five).
India Cancer Diagnostics Market is an upcoming
report to be released soon. If you wish an early delivery of this report or
want to confirm the date of release, please contact us at [email protected]